, I mean some aspect of a deal that is too severe in risk and nature to allow the deal to continue. There are a few black and white private equity deal killers, but also many shades of grey.
We all have our own biases and this is especially true for the private equiteer who has sourced a deal. We look for reasons to do the deal and downplay the reasons not to.
The solution to this is to have a set list of deal killers and to stick to that list regardless. The problem of course is that you could miss great deals and there’s merit in looking at deals on a case-by-case basis. But I’m sticking by
, because you simply don’t need to take undue risk. The following list is not exhaustive, but outlines a few scenarios in which I’d kill a deal (and after all, there’s a rank and file in a private equity firm for a reason):
I know I’ve been quite opinionated in this post and I concede that in a day, week or month, I may change my mind on some of these issues. But, I’ve witnessed a lot of self-fulfilling analysis lately and think it’s important to maintain objectivity in this climate. As the cliché says:
. That is, if the deal looks like a lemon early, it probably is a lemon.
To recap, we care about working capital because it is a direct driver of free cash flow and everyone loves free cash, ergo, everyone cares about working capital. But, before we talk about improving working capital, it’s important we understand how to measure and monitor it. If we measure it in a consistent way, we’ll
Read More
When we talk about working capital in private equity, we may be referring to the financial monitoring value (current assets – current liabilities) or the financial analysis value (current assets – cash – current liabilities). When monitoring a business, we want to know if it is solvent; that is, whether the business can cover its
Read More